for subcutaneous use Initial U.S. Approval: 2019
As specified in the prescribing information, risankizumab-rzaa injection is indicated for the treatment of psoriasis . SKYRIZI is an interleukin-23 antagonist indicated for the treatment of: • moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. • active psoriatic arthritis in adults.
Facts about risankizumab-rzaa injection
Approval Date: 2019
Proprietary Name: SKYRIZI (risankizumab-rzaa) injection
Active Ingredient(s): risankizumab-rzaa
FDA-approved use: psoriasis
Dosage Form: • Injection: 150 mg/mL in each single-dose prefilled pen. • Injection: 150 mg/mL in each single-dose prefilled syringe. • Injection: 75 mg/0.83 mL in each single-dose prefilled syringe
Medicine Approved By: US FDA
Manufacturer: AbbVie Inc.
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)
Access the best support services globally
If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “risankizumab-rzaa injection” based on the information you provide.
Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.
MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
Query For risankizumab-rzaa injection
Approved accessible "risankizumab-rzaa injection"
Skyrizi (risankizumab-rzaa) injection, which was originally approved in 2019 for plaque psoriasis, was approved in 2022 to treat moderately to severely active Crohn’s disease, a type of inflammatory bowel disease. Skyrizi is the first new treatment for Crohn’s disease in six years. Skyrizi was also approved in 2022 for adults with active psoriatic arthritis, a systemic inflammatory disease that affects the skin and joints.
SKYRIZI is a prescription medicine used to treat adults: • with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy). • with active psoriatic arthritis (PsA). It is not known if SKYRIZI is safe and effective in children under 18 years of age. Active ingredient: risankizumab-rzaa SKYRIZI 150 mg/mL inactive ingredients: acetic acid, polysorbate 20, sodium acetate trihydrate, trehalose dihydrate, and Water for Injection, USP. SKYRIZI 75 mg/0.83 mL inactive ingredients: disodium succinate hexahydrate, polysorbate 20, sorbitol, succinic acid, and Water for Injection, USP.
How can 1 go about obtaining risankizumab-rzaa injection?
If risankizumab-rzaa injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).
SKYRIZI (risankizumab-rzaa) injection, for subcutaneous use Initial U.S. Approval: 2019
Indian Pharma Network (IPN), New Delhi. India
Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa
Indian Pharma Network
Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398